- Home
- SOR vs CGEM Comparison
SOR vs CGEM Comparison
Compare SOR & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOR
- CGEM
- Stock Information
- Founded
- SOR 1968
- CGEM 2016
- Country
- SOR United States
- CGEM United States
- Employees
- SOR N/A
- CGEM N/A
- Industry
- SOR Investment Managers
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- SOR Finance
- CGEM Health Care
- Exchange
- SOR Nasdaq
- CGEM Nasdaq
- Market Cap
- SOR 368.0M
- CGEM 437.2M
- IPO Year
- SOR N/A
- CGEM 2021
- Fundamental
- Price
- SOR $45.66
- CGEM $7.71
- Analyst Decision
- SOR
- CGEM Strong Buy
- Analyst Count
- SOR 0
- CGEM 7
- Target Price
- SOR N/A
- CGEM $26.00
- AVG Volume (30 Days)
- SOR 16.2K
- CGEM 1.5M
- Earning Date
- SOR 01-01-0001
- CGEM 11-07-2025
- Dividend Yield
- SOR 7.24%
- CGEM N/A
- EPS Growth
- SOR N/A
- CGEM N/A
- EPS
- SOR 6.50
- CGEM N/A
- Revenue
- SOR N/A
- CGEM N/A
- Revenue This Year
- SOR N/A
- CGEM N/A
- Revenue Next Year
- SOR N/A
- CGEM N/A
- P/E Ratio
- SOR $6.41
- CGEM N/A
- Revenue Growth
- SOR N/A
- CGEM N/A
- 52 Week Low
- SOR $36.41
- CGEM $5.68
- 52 Week High
- SOR $42.75
- CGEM $17.50
- Technical
- Relative Strength Index (RSI)
- SOR 50.61
- CGEM 52.37
- Support Level
- SOR $44.96
- CGEM $7.69
- Resistance Level
- SOR $46.00
- CGEM $8.57
- Average True Range (ATR)
- SOR 0.70
- CGEM 0.65
- MACD
- SOR -0.03
- CGEM -0.03
- Stochastic Oscillator
- SOR 36.59
- CGEM 24.32
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.